The biosimilar brand of etanercept Rymti, Etera has been approved by the TGA for use in conditions including rheumatoid arthritis, psoriatic arthritis and non-radiographic axial spondyloarthritis. The TNF inhibitor, marketed by Lupin Australia is indicated for the treatment of RA, PsA, nr-AxSpa, ankylosing spondylitis, juvenile idiopathic arthritis and plaque psoriasis. It is a biosimilar for ...
Another etanercept biosimilar approved for arthritic conditions
14 Oct 2020